Search

Your search keyword '"Traini, Sara"' showing total 24 results
Start Over Author "Traini, Sara"
24 results on '"Traini, Sara"'

1. Efficacy of an inactivated EHDV-8 vaccine in preventing viraemia and clinical signs in experimentally infected cattle

Author

Spedicato, Massimo, Ronchi, Gaetano Federico, Profeta, Francesca, Traini, Sara, Capista, Sara, Leone, Alessandra, Iorio, Mariangela, Portanti, Ottavio, Palucci, Cristiano, Pulsoni, Simone, Testa, Lilia, Serroni, Anna, Rossi, Emanuela, Armillotta, Gisella, Laguardia, Caterina, D'Alterio, Nicola, Savini, Giovanni, Di Ventura, Mauro, Lorusso, Alessio, and Mercante, Maria Teresa

Published
2024
Full Text
View/download PDF

3. Supplementary Figure 1 from Inhibition of Tumor Growth and Angiogenesis by SP-2, an Anti–Lectin, Galactoside-Binding Soluble 3 Binding Protein (LGALS3BP) Antibody

Author

Traini, Sara, primary, Piccolo, Enza, primary, Tinari, Nicola, primary, Rossi, Cosmo, primary, La Sorda, Rossana, primary, Spinella, Francesca, primary, Bagnato, Anna, primary, Lattanzio, Rossano, primary, D'Egidio, Maurizia, primary, Di Risio, Annalisa, primary, Tomao, Federica, primary, Grassadonia, Antonino, primary, Piantelli, Mauro, primary, Natoli, Clara, primary, and Iacobelli, Stefano, primary

Published
2023
Full Text
View/download PDF

4. Supplementary Figure Legend from Inhibition of Tumor Growth and Angiogenesis by SP-2, an Anti–Lectin, Galactoside-Binding Soluble 3 Binding Protein (LGALS3BP) Antibody

Author

Traini, Sara, primary, Piccolo, Enza, primary, Tinari, Nicola, primary, Rossi, Cosmo, primary, La Sorda, Rossana, primary, Spinella, Francesca, primary, Bagnato, Anna, primary, Lattanzio, Rossano, primary, D'Egidio, Maurizia, primary, Di Risio, Annalisa, primary, Tomao, Federica, primary, Grassadonia, Antonino, primary, Piantelli, Mauro, primary, Natoli, Clara, primary, and Iacobelli, Stefano, primary

Published
2023
Full Text
View/download PDF

7. Management of biliary anastomotic strictures after liver transplantation (BASALT study): A nationwide Italian survey

Author

Cantù, Paolo, Parzanese, Ilaria, Balassone, Valerio, Di Sario, Antonio, Soggiu, Fiammetta, Lombardi, Giovanni, Barbaro, Federico, Pisani, Antonio, Baldan, Anna, Cariani, Giulio, Boarino, Valentina, Fasoli, Alberto, Bertani, Helga, Forti, Edoardo, Bulajic, Milutin, Ghinolfi, Davide, Nadal, Elena, Cerofolini, Angelo, Barresi, Luca, Catalano, Giorgia, Stroppa, Italo, Traini, Sara, Mazzaferro, Vincenzo, Cipolletta, Livio, Tringali, Andrea, Costamagna, Guido, Ravelli, Paolo, Bazzoli, Franco, Merighi, Alberto, Parodi, Maria Caterina, Conigliaro, Rita, Mutignani, Massimiliano, Zilli, Maurizio, Filipponi, Franco, Fantin, Alberto, Rodella, Luca, Tarantino, Ilaria, Traina, Mario, Salizzoni, Mauro, Rosa, Roberto, Malinverno, Federica, Invernizzi, Federica, Angelo Manini, Matteo, Donato, Maria Francesca, Colombo, Massimo, Conte, Dario, Rossi, Giorgio, and Penagini, Roberto

Published
2017
Full Text
View/download PDF

8. LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis

Author

Piccolo, Enza, Tinari, Nicola, Semeraro, Daniela, Traini, Sara, Fichera, Imma, Cumashi, Albana, La Sorda, Rossana, Spinella, Francesca, Bagnato, Anna, Lattanzio, Rossano, D’Egidio, Maurizia, Di Risio, Annalisa, Stampolidis, Pavlos, Piantelli, Mauro, Natoli, Clara, Ullrich, Axel, and Iacobelli, Stefano

Published
2013
Full Text
View/download PDF

9. Management of biliary anastomotic strictures after liver transplantation (BASALT study): A nationwide Italian survey

Author

Cantu', Paolo, Parzanese, Ilaria, Balassone, Valerio, Di Sario, Antonio, Soggiu, Fiammetta, Lombardi, Giovanni, Barbaro, Federico, Pisani, Antonio, Baldan, Anna, Cariani, Giulio, Boarino, Valentina, Fasoli, Alberto, Bertani, Helga, Forti, Edoardo, Bulajic, Milutin, Ghinolfi, Davide, Nadal, Elena, Cerofolini, Angelo, Barresi, Luca, Catalano, Giorgia, Stroppa, Italo, Traini, Sara, Mazzaferro, Vincenzo, Cipolletta, Livio, Tringali, Andrea, Costamagna, Guido, Ravelli, Paolo, Bazzoli, Franco, Merighi, Alberto, Parodi, Maria Caterina, Conigliaro, Rita, Mutignani, Massimiliano, Zilli, Maurizio, Filipponi, Franco, Fantin, Alberto, Rodella, Luca, Tarantino, Ilaria, Traina, Mario, Salizzoni, Mauro, Rosa, Roberto, Malinverno, Federica, Invernizzi, Federica, Angelo Manini, Matteo, Donato, Maria Francesca, Colombo, Massimo, Conte, Dario, Rossi, Giorgio, Penagini, Roberto, Tringali, Andrea (ORCID:0000-0002-9614-3449), Costamagna, Guido (ORCID:0000-0002-8100-2731), Mutignani, Massimiliano (ORCID:0000-0002-1272-4888), Cantu', Paolo, Parzanese, Ilaria, Balassone, Valerio, Di Sario, Antonio, Soggiu, Fiammetta, Lombardi, Giovanni, Barbaro, Federico, Pisani, Antonio, Baldan, Anna, Cariani, Giulio, Boarino, Valentina, Fasoli, Alberto, Bertani, Helga, Forti, Edoardo, Bulajic, Milutin, Ghinolfi, Davide, Nadal, Elena, Cerofolini, Angelo, Barresi, Luca, Catalano, Giorgia, Stroppa, Italo, Traini, Sara, Mazzaferro, Vincenzo, Cipolletta, Livio, Tringali, Andrea, Costamagna, Guido, Ravelli, Paolo, Bazzoli, Franco, Merighi, Alberto, Parodi, Maria Caterina, Conigliaro, Rita, Mutignani, Massimiliano, Zilli, Maurizio, Filipponi, Franco, Fantin, Alberto, Rodella, Luca, Tarantino, Ilaria, Traina, Mario, Salizzoni, Mauro, Rosa, Roberto, Malinverno, Federica, Invernizzi, Federica, Angelo Manini, Matteo, Donato, Maria Francesca, Colombo, Massimo, Conte, Dario, Rossi, Giorgio, Penagini, Roberto, Tringali, Andrea (ORCID:0000-0002-9614-3449), Costamagna, Guido (ORCID:0000-0002-8100-2731), and Mutignani, Massimiliano (ORCID:0000-0002-1272-4888)

Abstract

Anastomotic stricture (AS) can occur in 10%-30% ofliver transplantation (LT) patients leading to liver dysfunction. Its diagnostic workup does not rely on a standard protocol or any international consensus of experts, thus AS management can considerably differ among centers. This affects the selection of patients after LT for endotherapy and, ultimately, results. Endotherapy is considered the reference standard treatment for AS,(2,3) but approach differs among centers depending on local expertise. The aim of the present retrospective survey was to report both the volume of endoscopic retrograde cholangiopancreatographies (ERCPs) dedicated to duct-to-duct AS treatment and the extent of variability in the management of AS at the Italian units involved in endotherapy of LT patients.

Published
2017

10. Two‐year effectiveness and safety of golimumab in ulcerative colitis: An IG‐IBD study

Author

Pugliese, Daniela, Privitera, Giuseppe, Rogai, Francesca, Variola, Angela, Viola, Anna, Laterza, Lucrezia, Privitera, Antonino C., Allocca, Mariangela, Bossa, Fabrizio, Cappello, Maria, Daperno, Marco, Lorenzon, Greta, Mazzuoli, Silvia, Principi, Mariabeatrice, Sablich, Renato, Moser, Luisa, Ferronato, Antonio, Traini, Sara, Tapete, Gherardo, Bodini, Giorgia, Di Girolamo, Maria, Grossi, Laurino, Mocci, Giammarco, Ricci, Chiara, Saibeni, Simone, Festa, Stefano, Spagnuolo, Rocco, Cortelezzi, Claudio C., Mocciaro, Filippo, Rizzello, Fernando, and Armuzzi, Alessandro

Abstract

Few data exist regarding the long‐term effectiveness of golimumab in ulcerative colitis. No data have been reported on real‐world continuous clinical response. This study aimed to describe the long‐term outcomes in a large cohort of patients on golimumab who had ulcerative colitis. Consecutive patients with active ulcerative colitis, started on golimumab, were enrolled and prospectively followed up. The primary end point was to evaluate the long‐term persistence on golimumab therapy. A total of 173 patients with ulcerative colitis were studied. Of these, 79.2% were steroid dependent, and 46.3% were naïve to anti‐tumour necrosis factor alpha agents. The median duration of golimumab therapy was 52 weeks (range: 4–142 weeks). The cumulative probability of maintaining golimumab treatment was 47.3% and 22.5% at 54 and 108 weeks, respectively. Biological‐naïve status (odds ratio [OR] = 3.02, 95% confidence interval [CI]: 1.44–6.29; p= 0.003) and being able to discontinue steroids at Week 8 (OR = 3.32, 95% CI: 1.34–8.30; p= 0.010) and Week 14 (OR = 2.94, 95% CI: 1.08–8.02; p= 0.036) were associated with longer persistence on therapy. At Week 54, 65/124 (52.4%) postinduction responders were in continuous clinical response. A continuous clinical response was associated with a lower likelihood of golimumab discontinuation throughout the subsequent year of therapy (p< 0.01). Overall, 40 (23.1%) patients were in clinical remission at the last follow‐up visit. Twenty‐six adverse events were recorded, leading to golimumab withdrawal in 9.2% of patients. : Biological‐naïve status and not requiring steroids at Weeks 8 and 14 seem to be associated with a longer persistence on golimumab therapy in ulcerative colitis.

Published
2021
Full Text
View/download PDF

11. Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study

Author

Pugliese, Daniela, Privitera, Giuseppe, Rogai, Francesca, Variola, Angela, Viola, Anna, Laterza, Lucrezia, Privitera, Antonino Carlo, Allocca, Mariangela, Bossa, Fabrizio, Cappello, Maria, Daperno, Marco, Lorenzon, Greta, Mazzuoli, Silvia, Principi, Mariabeatrice, Sablich, Renato, Moser, Luisa, Ferronato, Antonio, Traini, Sara, Tapete, Gherardo, Bodini, Giorgia, Girolamo, Maria Di, Grossi, Laurino, Mocci, Giammarco, Ricci, Chiara, Saibeni, Simone, Festa, Stefano, Spagnuolo, Rocco, Cortelezzi, Claudio Camillo, Mocciaro, Filippo, Rizzello, Fernando, and Armuzzi, Alessandro

Abstract

Background Few data exist regarding the long-term effectiveness of golimumab in ulcerative colitis. No data have been reported on real-world continuous clinical response.Objective This study aimed to describe the long-term outcomes in a large cohort of patients on golimumab who had ulcerative colitis.Methods Consecutive patients with active ulcerative colitis, started on golimumab, were enrolled and prospectively followed up. The primary end point was to evaluate the long-term persistence on golimumab therapy.Results A total of 173 patients with ulcerative colitis were studied. Of these, 79.2% were steroid dependent, and 46.3% were naïve to anti-tumour necrosis factor alpha agents. The median duration of golimumab therapy was 52 weeks (range 4–142 weeks). The cumulative probability of maintaining golimumab treatment was 47.3% and 22.5% at 54 and 108 weeks, respectively. Biological-naïve status (odds ratio (OR) = 3.02, 95% confidence interval (CI) 1.44–6.29, p= 0.003) and being able to discontinue steroids at week 8 (OR = 3.32, 95% CI 1.34–8.30, p= 0.010) and week 14 (OR = 2.94, 95% CI 1.08–8.02, p= 0.036) were associated with longer persistence on therapy. At week 54, 65/124 (52.4%) post-induction responders were in continuous clinical response. A continuous clinical response was associated with a lower likelihood of golimumab discontinuation throughout the subsequent year of therapy (p< 0.01). Overall, 40 (23.1%) patients were in clinical remission at the last follow-up visit. Twenty-six adverse events were recorded, leading to golimumab withdrawal in 9.2% of patients.Conclusions Biological-naïve status and not requiring steroids at weeks 8 and 14 seem to be associated with a longer persistence on golimumab therapy in ulcerative colitis.

Published
2024
Full Text
View/download PDF

12. EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo1

Author

Sala, Gianluca, Rapposelli, Ilario Giovanni, Ghasemi, Reza, Piccolo, Enza, Traini, Sara, Capone, Emily, Rossi, Cosmo, Pelliccia, Angela, Di Risio, Annalisa, D'Egidio, Maurizia, Tinari, Nicola, Muraro, Raffaella, and Iacobelli, Stefano

Subjects
Research Article
Abstract

ErbB-3 (HER-3) receptor is involved in tumor progression and resistance to therapy. Development of specific inhibitors impairing the activity of ErbB-3 is an attractive tool for cancer therapeutics. MP-RM-1, a murine monoclonal antibody targeting human ErbB-3, has shown anticancer activity in preclinical models. With the aim to provide novel candidates for clinical use, we have successfully generated a humanized version of MP-RM-1. The humanized antibody, named EV20, abrogates both ligand-dependent and ligand-independent receptor signaling of several tumor cell types, strongly promotes ErbB-3 down-regulation, and efficiently and rapidly internalizes into tumor cells. Furthermore, treatment with EV20 significantly inhibits growth of xenografts originating from prostatic, ovarian, and pancreatic cancers as well as melanoma in nude mice. In conclusion, we provide a novel candidate for ErbB-3-targeted cancer therapy.

Published
2013

14. Inhibition of Tumor Growth and Angiogenesis by SP-2, an Anti–Lectin, Galactoside-Binding Soluble 3 Binding Protein (LGALS3BP) Antibody

Author

Traini, Sara, primary, Piccolo, Enza, additional, Tinari, Nicola, additional, Rossi, Cosmo, additional, La Sorda, Rossana, additional, Spinella, Francesca, additional, Bagnato, Anna, additional, Lattanzio, Rossano, additional, D'Egidio, Maurizia, additional, Di Risio, Annalisa, additional, Tomao, Federica, additional, Grassadonia, Antonino, additional, Piantelli, Mauro, additional, Natoli, Clara, additional, and Iacobelli, Stefano, additional

Published
2014
Full Text
View/download PDF

15. EV20, a Novel Anti-ErbB-3 Humanized Antibody, Promotes ErbB-3 Down-Regulation and Inhibits Tumor Growth In Vivo

Author

Sala, Gianluca, primary, Giovanni Rapposelli, Ilario, additional, Ghasemi, Reza, additional, Piccolo, Enza, additional, Traini, Sara, additional, Capone, Emily, additional, Rossi, Cosmo, additional, Pelliccia, Angela, additional, Di Risio, Annalisa, additional, D'Egidio, Maurizia, additional, Tinari, Nicola, additional, Muraro, Raffaella, additional, and Iacobelli, Stefano, additional

Published
2013
Full Text
View/download PDF

16. Diacylglycerol kinase-alpha mediates hepatocyte growth factor-induced epithelial cell scatter by regulating Rac activation and membrane ruffling.

Author

Chianale, Federica, Cutrupi, Santina, Rainero, Elena, Baldanzi, Gianluca, Porporato, Paolo, Traini, Sara, Filigheddu, Nicoletta, Gnocchi, Viola F, Santoro, Massimo M, Parolini, Ornella, van Blitterswijk, Wim J, Sinigaglia, Fabiola, Graziani, Andrea, Chianale, Federica, Cutrupi, Santina, Rainero, Elena, Baldanzi, Gianluca, Porporato, Paolo, Traini, Sara, Filigheddu, Nicoletta, Gnocchi, Viola F, Santoro, Massimo M, Parolini, Ornella, van Blitterswijk, Wim J, Sinigaglia, Fabiola, and Graziani, Andrea

Abstract

Diacylglycerol kinases (Dgk) phosphorylate diacylglycerol (DG) to phosphatidic acid (PA), thus turning off and on, respectively, DG-mediated and PA-mediated signaling pathways. We previously showed that hepatocyte growth factor (HGF), vascular endothelial growth factor, and anaplastic lymphoma kinase activate Dgkalpha in endothelial and leukemia cells through a Src-mediated mechanism and that activation of Dgkalpha is required for chemotactic, proliferative, and angiogenic signaling in vitro. Here, we investigate the downstream events and signaling pathways regulated by Dgkalpha, leading to cell scatter and migration upon HGF treatment and v-Src expression in epithelial cells. We report that specific inhibition of Dgkalpha, obtained either pharmacologically by R59949 treatment, or by expression of Dgkalpha dominant-negative mutant, or by small interfering RNA-mediated down-regulation of endogenous Dgkalpha, impairs 1) HGF- and v-Src-induced cell scatter and migration, without affecting the loss of intercellular adhesions; 2) HGF-induced cell spreading, lamellipodia formation, membrane ruffling, and focal adhesions remodeling; and 3) HGF-induced Rac activation and membrane targeting. In summary, we provide evidence that Dgkalpha, activated downstream of tyrosine kinase receptors and Src, regulates crucial steps directing Rac activation and Rac-dependent remodeling of actin cytoskeleton and focal contacts in migrating epithelial cells.

Published
2007

17. LGALS3BP, lectin galactoside-binding soluble 3 binding protein, induces vascular endothelial growth factor in human breast cancer cells and promotes angiogenesis

Author

Piccolo, Enza, primary, Tinari, Nicola, additional, Semeraro, Daniela, additional, Traini, Sara, additional, Fichera, Imma, additional, Cumashi, Albana, additional, La Sorda, Rossana, additional, Spinella, Francesca, additional, Bagnato, Anna, additional, Lattanzio, Rossano, additional, D’Egidio, Maurizia, additional, Di Risio, Annalisa, additional, Stampolidis, Pavlos, additional, Piantelli, Mauro, additional, Natoli, Clara, additional, Ullrich, Axel, additional, and Iacobelli, Stefano, additional

Published
2012
Full Text
View/download PDF

18. SAP-Mediated Inhibition of Diacylglycerol Kinase α Regulates TCR-Induced Diacylglycerol Signaling

Author

Baldanzi, Gianluca, primary, Pighini, Andrea, additional, Bettio, Valentina, additional, Rainero, Elena, additional, Traini, Sara, additional, Chianale, Federica, additional, Porporato, Paolo E., additional, Filigheddu, Nicoletta, additional, Mesturini, Riccardo, additional, Song, Shuping, additional, Schweighoffer, Tamas, additional, Patrussi, Laura, additional, Baldari, Cosima T., additional, Zhong, Xiao-Ping, additional, van Blitterswijk, Wim J., additional, Sinigaglia, Fabiola, additional, Nichols, Kim E., additional, Rubio, Ignacio, additional, Parolini, Ornella, additional, and Graziani, Andrea, additional

Published
2011
Full Text
View/download PDF

20. Diacylglycerol Kinase-α Mediates Hepatocyte Growth Factor-induced Epithelial Cell Scatter by Regulating Rac Activation and Membrane Ruffling

Author

Chianale, Federica, primary, Cutrupi, Santina, additional, Rainero, Elena, additional, Baldanzi, Gianluca, additional, Porporato, Paolo E., additional, Traini, Sara, additional, Filigheddu, Nicoletta, additional, Gnocchi, Viola F., additional, Santoro, Massimo M., additional, Parolini, Ornella, additional, van Blitterswijk, Wim J., additional, Sinigaglia, Fabiola, additional, and Graziani, Andrea, additional

Published
2007
Full Text
View/download PDF

21. Ghrelin and Des-Acyl Ghrelin Promote Differentiation and Fusion of C2C12 Skeletal Muscle Cells

Author

Filigheddu, Nicoletta, primary, Gnocchi, Viola F., additional, Coscia, Marco, additional, Cappelli, Miriam, additional, Porporato, Paolo E., additional, Taulli, Riccardo, additional, Traini, Sara, additional, Baldanzi, Gianluca, additional, Chianale, Federica, additional, Cutrupi, Santina, additional, Arnoletti, Elisa, additional, Ghè, Corrado, additional, Fubini, Alberto, additional, Surico, Nicola, additional, Sinigaglia, Fabiola, additional, Ponzetto, Carola, additional, Muccioli, Giampiero, additional, Crepaldi, Tiziana, additional, and Graziani, Andrea, additional

Published
2007
Full Text
View/download PDF

22. Management of biliary anastomotic strictures after liver transplantation (BASALT study): A nationwide Italian survey

Author

Roberto Penagini, Rita Conigliaro, Mauro Salizzoni, Dario Conte, Maria Francesca Donato, Federico Barbaro, Giorgia Catalano, Giovanni Lombardi, Davide Ghinolfi, Helga Bertani, Guido Costamagna, Livio Cipolletta, Elena Nadal, Roberto Rosa, Antonio Pisani, Antonio Di Sario, Andrea Tringali, Luca Rodella, Massimo Colombo, Massimiliano Mutignani, Milutin Bulajic, Ilaria Parzanese, Valentina Boarino, Angelo Cerofolini, Matteo Angelo Manini, Federica Malinverno, Giulio Cariani, Franco Filipponi, Luca Barresi, Edoardo Forti, Alberto Fasoli, Franco Bazzoli, Ilaria Tarantino, Sara Traini, Vincenzo Mazzaferro, Valerio Balassone, Mario Traina, Alberto Fantin, Paolo Cantù, Fiammetta Soggiu, Giorgio Rossi, Italo Stroppa, Maurizio Zilli, Federica Invernizzi, Alberto Merighi, Maria Caterina Parodi, Paolo Ravelli, Anna Baldan, Cantù, Paolo, Parzanese, Ilaria, Balassone, Valerio, Di Sario, Antonio, Soggiu, Fiammetta, Lombardi, Giovanni, Barbaro, Federico, Pisani, Antonio, Baldan, Anna, Cariani, Giulio, Boarino, Valentina, Fasoli, Alberto, Bertani, Helga, Forti, Edoardo, Bulajic, Milutin, Ghinolfi, Davide, Nadal, Elena, Cerofolini, Angelo, Barresi, Luca, Catalano, Giorgia, Stroppa, Italo, Traini, Sara, Mazzaferro, Vincenzo, Cipolletta, Livio, Tringali, Andrea, Costamagna, Guido, Ravelli, Paolo, Bazzoli, Franco, Merighi, Alberto, Parodi, Maria Caterina, Conigliaro, Rita, Mutignani, Massimiliano, Zilli, Maurizio, Filipponi, Franco, Fantin, Alberto, Rodella, Luca, Tarantino, Ilaria, Traina, Mario, Salizzoni, Mauro, Rosa, Roberto, Malinverno, Federica, Invernizzi, Federica, Angelo Manini, Matteo, Donato, Maria Francesca, Colombo, Massimo, Conte, Dario, Rossi, Giorgio, and Penagini, Roberto

Subjects
medicine.medical_specialty, Settore MED/12 - GASTROENTEROLOGIA, medicine.medical_treatment, Treatment outcome, Constriction, Pathologic, 030230 surgery, Anastomosis, Liver transplantation, Follow-Up Studie, 03 medical and health sciences, 0302 clinical medicine, Postoperative Complications, Surgery, Hepatology, Transplantation, Retrospective Studie, Internal medicine, Surveys and Questionnaires, medicine, Stent, Humans, Surveys and Questionnaire, Retrospective Studies, Cholangiopancreatography, Endoscopic Retrograde, Cholestasis, business.industry, Patient Selection, Follow up studies, biliary anastomotic strictures, Bile Duct, Retrospective cohort study, Liver Transplantation, Treatment Outcome, Multicenter study, Italy, Cholestasi, 030211 gastroenterology & hepatology, Stents, Bile Ducts, Postoperative Complication, business, Hospitals, High-Volume, Magnetic Resonance Angiography, Follow-Up Studies, Human
Abstract

n/a

Published
2017

23. SAP-mediated inhibition of diacylglycerol kinase α regulates TCR-induced diacylglycerol signaling

Author

Xiao-Ping Zhong, Nicoletta Filigheddu, Cosima T. Baldari, Valentina Bettio, Fabiola Sinigaglia, Andrea Pighini, Elena Rainero, Riccardo Mesturini, Laura Patrussi, Gianluca Baldanzi, Federica Chianale, Ignacio Rubio, Paolo E. Porporato, Shu-Ping Song, Wim J. van Blitterswijk, Sara Traini, Andrea Graziani, Kim E. Nichols, Ornella Parolini, Tamás Schweighoffer, UCL - SSS/IREC - Institut de recherche expérimentale et clinique, UCL - SSS/IREC/FATH - Pôle de Pharmacologie et thérapeutique, Baldanzi, Gianluca, Pighini, Andrea, Bettio, Valentina, Rainero, Elena, Traini, Sara, Chianale, Federica, Porporato, Paolo E., Filigheddu, Nicoletta, Mesturini, Riccardo, Song, Shuping, Schweighoffer, Tama, Patrussi, Laura, Baldari, Cosima T., Zhong, Xiao Ping, Van Blitterswijk, Wim J., Sinigaglia, Fabiola, Nichols, Kim E., Rubio, Ignacio, Parolini, Ornella, and Graziani, Andrea

Subjects
Diacylglycerol Kinase, Diglyceride, molecular adaptors, T-Lymphocytes, Blotting, Western, Immunology, Receptors, Antigen, T-Cell, immunoreceptor signaling, Fluorescent Antibody Technique, Jurkat Cell, Biology, Lymphocyte Activation, Transfection, lipid kinase, Jurkat cells, Article, SH3 domain, Diglycerides, Jurkat Cells, Humans, Immunoprecipitation, Immunology and Allergy, Settore BIO/13 - BIOLOGIA APPLICATA, Signaling Lymphocytic Activation Molecule Associated Protein, Protein kinase C, TCR, Diacylglycerol kinase, Intracellular Signaling Peptides and Proteins, Protein Transport, Signal Transduction, Kinase, T-cell receptor, Signal transducing adaptor protein, Cell biology, T-Lymphocyte, Intracellular Signaling Peptides and Protein, Signal transduction, Human
Abstract

Diacylglycerol kinases (DGKs) metabolize diacylglycerol to phosphatidic acid. In T lymphocytes, DGKα acts as a negative regulator of TCR signaling by decreasing diacylglycerol levels and inducing anergy. In this study, we show that upon costimulation of the TCR with CD28 or signaling lymphocyte activation molecule (SLAM), DGKα, but not DGKζ, exits from the nucleus and undergoes rapid negative regulation of its enzymatic activity. Inhibition of DGKα is dependent on the expression of SAP, an adaptor protein mutated in X-linked lymphoproliferative disease, which is essential for SLAM-mediated signaling and contributes to TCR/CD28-induced signaling and T cell activation. Accordingly, overexpression of SAP is sufficient to inhibit DGKα, whereas SAP mutants unable to bind either phospho-tyrosine residues or SH3 domain are ineffective. Moreover, phospholipase C activity and calcium, but not Src-family tyrosine kinases, are also required for negative regulation of DGKα. Finally, inhibition of DGKα in SAP-deficient cells partially rescues defective TCR/CD28 signaling, including Ras and ERK1/2 activation, protein kinase Cθ membrane recruitment, induction of NF-AT transcriptional activity, and IL-2 production. Thus SAP-mediated inhibition of DGKα sustains diacylglycerol signaling, thereby regulating T cell activation, and it may represent a novel pharmacological strategy for X-linked lymphoproliferative disease treatment. Copyright©2011 by The American Association of Immunologists, Inc.

Published
2011

24. Diacylglycerol kinase-alpha mediates hepatocyte growth factor-induced epithelial cell scatter by regulating Rac activation and membrane ruffling.

Author

Chianale F, Cutrupi S, Rainero E, Baldanzi G, Porporato PE, Traini S, Filigheddu N, Gnocchi VF, Santoro MM, Parolini O, van Blitterswijk WJ, Sinigaglia F, and Graziani A

Subjects
Animals, Cadherins metabolism, Cell Adhesion drug effects, Cell Line, Cell Membrane drug effects, Cell Movement drug effects, Cytoskeleton drug effects, Cytoskeleton metabolism, Diacylglycerol Kinase genetics, Down-Regulation drug effects, Enzyme Activation drug effects, Epithelial Cells cytology, Humans, Protein Binding, Cell Differentiation drug effects, Cell Membrane enzymology, Diacylglycerol Kinase metabolism, Epithelial Cells drug effects, Epithelial Cells enzymology, Hepatocyte Growth Factor pharmacology, rac GTP-Binding Proteins metabolism
Abstract

Diacylglycerol kinases (Dgk) phosphorylate diacylglycerol (DG) to phosphatidic acid (PA), thus turning off and on, respectively, DG-mediated and PA-mediated signaling pathways. We previously showed that hepatocyte growth factor (HGF), vascular endothelial growth factor, and anaplastic lymphoma kinase activate Dgkalpha in endothelial and leukemia cells through a Src-mediated mechanism and that activation of Dgkalpha is required for chemotactic, proliferative, and angiogenic signaling in vitro. Here, we investigate the downstream events and signaling pathways regulated by Dgkalpha, leading to cell scatter and migration upon HGF treatment and v-Src expression in epithelial cells. We report that specific inhibition of Dgkalpha, obtained either pharmacologically by R59949 treatment, or by expression of Dgkalpha dominant-negative mutant, or by small interfering RNA-mediated down-regulation of endogenous Dgkalpha, impairs 1) HGF- and v-Src-induced cell scatter and migration, without affecting the loss of intercellular adhesions; 2) HGF-induced cell spreading, lamellipodia formation, membrane ruffling, and focal adhesions remodeling; and 3) HGF-induced Rac activation and membrane targeting. In summary, we provide evidence that Dgkalpha, activated downstream of tyrosine kinase receptors and Src, regulates crucial steps directing Rac activation and Rac-dependent remodeling of actin cytoskeleton and focal contacts in migrating epithelial cells.

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results